ENTA—After listening to the CC and further contemplating the EDP-305 dataset reported today, I think ENTA should strongly consider switching from EDP-305 to the company's backup FXR compound.
EDP-305's pruritis rate at 2.5mg is too high, and it's unclear whether there's a bona fide therapeutic window for this drug.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.